Lenalidomide acts on the NF-κB pathway by targeting the E3 ubiquitin ligase component of cereblon, and shows substantial activity in patients with relapsed or refractory DLBCL alone or in combination with other regimens (Wiernik et al., 2008; Hernandez-Ilizaliturri et al., 2011; Witzig et al., 2011; Zinzani et al., 2011; Hitz et al., 2013; Wang et al., 2013; Zhang et al., 2013; Feldman et al., 2014; Hitz et al., 2016; Martin et al., 2016; Czuczman et al., 2017; Ferreri et al., 2017). Here, NFKB1 is linked to diffuse large B-cell lymphoma.